Vyant Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
16 Novembre 2022 - 10:43PM
Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an
innovative biotechnology company reinventing drug discovery for
complex neurodevelopmental and neurodegenerative disorders. The
Company’s proprietary central nervous system (“CNS”) drug discovery
platform combines human-derived organoid models of brain disease,
scaled biology, and machine learning. Today, Vyant Bio announced
that the Company has received formal notice from The Nasdaq Stock
Market LLC (“Nasdaq”) stating that the Company has regained
compliance with the minimum bid price requirement (Nasdaq Listing
Rule 5550(a)(2)) for continued listing on The Nasdaq Capital
Market.
The notice the Company received from Nasdaq on
November 16, 2022 noted that the Company evidenced a closing bid
price of its shares of common stock at or greater than the $1.00
per share minimum requirement for the last 10 consecutive business
days.
ABOUT VYANT BIO, INC.
Vyant Bio, Inc. (“Vyant Bio” or the “Company”)
(Nasdaq: VYNT) is an innovative biotechnology company focused on
identifying unique biological targets and novel and repurposed
therapeutics. Vyant Bio has built a platform of therapeutics
seeking to treat neurodevelopmental and neurodegenerative diseases,
with current programs targeting Rett Syndrome (“Rett”), CDKL5
Deficiency Disorders (“CDD”), and Parkinson’s Disease. The
Company’s approach to drug discovery integrates human-derived
biology with artificial intelligence and machine learning
technologies to de-risk candidate selection, with the goal of
improving the potential effectiveness of drugs discovered earlier
in the development cycle. Vyant Bio’s management believes that drug
discovery needs to progressively shift to more efficient methods as
the widely used models for predicting safe and effective drugs have
under-performed, as evidenced by the significant time and cost of
bringing novel drugs to patients. By combining sophisticated data
science capabilities with highly functional human cell derived
disease models, Vyant Bio seeks to leverage its current ability to
screen and test therapeutic candidates, and create a unique
approach to assimilating data that supports decision making
iteratively throughout the discovery phase of drug development to
identify both novel and repurposed CNS therapeutic candidates.
For more information, please visit or
follow Vyant Bio
at:Internet: www.vyantbio.com
LinkedIn: https://www.linkedin.com/company/vyant-bio
Twitter: @VyantBio
Forward Looking Statements:
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s
expectations regarding future financial and/or operating results,
the efficacy of our drug screening and discovery process, and
potential for our services, future revenue or growth in this press
release constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to, statements
that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” and “estimates”) should also be
considered to be forward-looking statements. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in our attempts to discover drug
candidates, partner with pharmaceutical and other biotechnology
companies, achieve profitability, adapt to the global coronavirus
pandemic, raise capital to meet our liquidity needs, and other
risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended
December 31, 2021, and any subsequent filings with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Vyant Bio disclaims
any obligation to update these forward-looking statements.
Investor Contact:Skyline Corporate
Communications Group, LLCScott Powell, PresidentOne Rockefeller
Plaza, 10th FloorNew York, NY 10020 USAOffice: (646) 893-5835
x2Email: info@skylineccg.com
###
Grafico Azioni Vyant Bio (NASDAQ:VYNT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Vyant Bio (NASDAQ:VYNT)
Storico
Da Giu 2023 a Giu 2024